EMBL Courses and Conferences during the Coronavirus pandemic
With the onsite programme paused, many of our events are now being offered in virtual formats.
Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.
More information for participants of events at EMBL Heidelberg can be found here.
This course will provide hands-on training in genome editing and cell engineering in mammalian cells and mouse embryos using the highly efficient CRISPR/Cas9 system. Participants will learn design of CRISPR targets using bioinformatics tools, generation of gene knock-outs/knock-ins, and target validation using the most current technologies. The course will be split into two groups (mammalian cells OR mice) based on participants' expertise.
This course is aimed at researchers who are familiar with basic molecular and cell biology techniques and who want to learn how to create an engineered mammalian cell line or mouse model using the most recent and advanced CRISPR/Cas9 system. No previous experience in genome editing is required.
During this course you will learn:
- How to design target specific CRISPR/Cas9 tools
- Generation of guide RNA (gRNA)
- Transfection optimisation for efficient gene editing
- Generation of knock-out and knock-in cell lines and mouse embryos
- Validation of genome-edited cell lines and embryos
After this course you should be able to:
- Design CRISPR based editing tools for your target gene of interest
- Choose the right format of gene editing tool and delivery strategy for your cell type or embryos
- Edit, screen and validate the engineered models, embryo manipulation
What Past Participants Say about the Course
"This course is very helpful even for beginners to overcome the barrier and access to CRISPR technique." - Seungmin Han, WT-CRUK Gurdon Institute, UK
"The EMBL Genome Engineering course provided me with knowledge, confidence and inspiration to use CRISPR/Cas technology." - Marina Kazantseva, University of Otago, New Zealand